静脉血栓栓塞症的慢性并发症
本文综述静脉血栓栓塞症(VTE)相关慢性并发症的流行病学、诊断与治疗。VTE常见(约每10万人700例),可致复发、慢性并发症和高达40%的10年死亡率。血栓溶解受损是血栓后综合征(PTS)与慢性血栓栓塞性肺动脉高压(CTEPH)的共同基础;有症状深静脉血栓后PTS发生率高达50%,肺栓塞后仅少数患者被诊断为CTEPH。
要点
- VTE约每10万人700例,10年死亡率报告高达40%。
- 血栓溶解受损是PTS与CTEPH的共同基础。
- 有症状深静脉血栓后PTS发生率高达50%,肺栓塞后仅少数且界定不清的患者被诊断为CTEPH。
核心结论
- 血栓溶解受损是VTE慢性并发症PTS与CTEPH的共同基础,二者致残率高、医疗费用高。
- 新型抗凝药已革新急性VTE治疗,但慢性并发症的预防与治疗策略仍缺乏同等里程碑式进展。
研究设计与样本
- 本文为综述,全面总结VTE相关慢性并发症的流行病学、诊断与治疗。
主要发现
- VTE为常见疾病(约每10万人700例),与显著复发风险、慢性并发症和相当高的死亡率相关,报告的10年死亡率高达40%。
- 有症状深静脉血栓后PTS发生率高达50%;肺栓塞后仅少数且界定不清的患者被诊断为CTEPH。
- PTS与CTEPH均与相当高的致残率和高昂医疗费用相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is a common disease (~700 per 100 000) that is associated with significant risk of recurrence, chronic complications, and substantial mortality, with reported death rates of up to 40% at 10 years. The development of novel anticoagulants has revolutionized the treatment of acute VTE, while strategies for prevention and treatment of chronic complications still seek for such a landmark change. Impaired thrombus resolution is the common denominator behind VTE complications, which are postthrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH). PTS and CTEPH are associated with substantial morbidity and high healthcare expenses. While PTS occurs in up to 50% of patients after symptomatic deep vein thrombosis, only a small and poorly defined number of patients are diagnosed with CTEPH after pulmonary embolism. This review is a comprehensive summary of VTE-related chronic complications, their epidemiology, diagnosis, and treatment.
引用
- Winter MP, Schernthaner GH, Lang IM, et al. Chronic complications of venous thromboembolism. J Thromb Haemost. 2017. PMID: 28762624. doi:10.1111/jth.13741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。